GlassScriptPhysician profile
Cynthia Page
NPI 1649287087
$5,916.79
in general payments reported to CMS, 2019-2025
28 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $876 · 2022: $904 · 2023: $682 · 2024: $2,916 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431 · Travel and Lodging: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.70 |
| Travel and Lodging | $1,706.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $2,296.45 | 2022-2025 | Barostim Neo System |
| Abbott Laboratories | $1,027.27 | 2021-2025 | Gallant, Merlin@Home, Jot Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $587.28 | 2021-2025 | Lifevest |
| Pfizer INC. | $262.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $210.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $170.22 | 2021-2024 | Verquvo |
| Medtronic, INC. | $167.17 | 2021-2024 | Cobalt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.05 | 2021-2024 | Jardiance |
| Amgen INC. | $139.01 | 2021-2025 | Repatha, Repatha, Tepezza |
| E.R. Squibb & Sons, L.L.C. | $138.78 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $127.39 | 2022-2024 | |
| Novo Nordisk INC | $81.02 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $73.53 | 2021-2023 | Farxiga |
| Boston Scientific Corporation | $60.66 | 2023-2025 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $58.27 | 2024-2025 | Onpattro, Amvuttra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.81 | 2024-2025 | |
| Daiichi Sankyo INC. | $46.02 | 2022-2024 | Injectafer |
| Esperion Therapeutics, INC. | $40.86 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $37.64 | 2021 | |
| Baxter Healthcare | $31.66 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $27.00 | 2025 | Attruby |
| Ibsa Pharma INC. | $23.02 | 2024 | Licart, Tirosint |
| Qol Medical, LLC | $18.77 | 2024 | Sucraid |
| Radius Health, INC. | $17.00 | 2024 | Tymlos |
| Kiniksa Pharmaceuticals, LTD. | $16.51 | 2022 | |
| Irhythm Technologies, INC. | $16.33 | 2022 | |
| Astellas Pharma US INC | $15.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.